CSBio CSBio

X
[{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Th\u00e9a Open Innovation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ripple Therapeutics"},{"orgOrder":0,"company":"Ripple Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Th\u00e9a Open Innovation","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Ripple Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The licensing deal with TOI includes a significant upfront payment, sizeable clinical and regulatory milestones and double-digit royalties. As part of the Licensing Agreement, TOI will also manage and finance the Phase III pivotal trials for IBE-814 IVT.

            Lead Product(s): Dexamethasone

            Therapeutic Area: Ophthalmology Product Name: IBE-814 IVT

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Laboratoires Thea

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Along with a Series A The licensing deal with TOI includes a significant upfront payment, sizeable clinical and regulatory milestones and double-digit royalties. As part of the Licensing Agreement, TOI will also manage and finance the Phase III pivotal trials for IBE-814 IVT.

            Lead Product(s): Dexamethasone

            Therapeutic Area: Ophthalmology Product Name: IBE-814 IVT

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Laboratoires Thea

            Deal Size: $22.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing December 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY